OR WAIT 15 SECS
September 7, 2016
The market for attention deficit hyperactivity disorder (ADHD) across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, is set to experience an increase from approximately $6.1 billion in 2014 to $13.9 billion by 2024, according to research and consulting firm GlobalData.
The company’s latest report states that the robust growth can be attributed to the launch of efficacious pipeline products with convenient oral formulations or less frequent dosing than currently available products, an increase in treatment rates, and the continued awareness and recognition of ADHD in the adult age group.
GlobalData analyst Rachel Markwick, Ph.D., commented: “Currently, the ADHD market is rife with unmet needs. These include a need for more treatment options, clinically relevant head-to-head comparisons between current marketed and pipeline drugs, improved diagnostic tests, and increased education and recognition of ADHD."
The report adds that the ADHD market would readily open up to both new and existing drugs that address other unmet needs in this space.